Cytosorbents (CTSO) officer Capponi receives equity awards, boosting holdings
Rhea-AI Filing Summary
Insider equity awards and holdings reported for Cytosorbents (CTSO). Officer Vincent Capponi was granted 89,100 restricted stock units (RSUs) and a stock option award for 111,100 shares on 08/08/2025. The RSUs vest in equal parts at the first and second anniversaries of the grant and certain RSUs will settle into common stock upon a defined Change in Control. The stock options vest over three years (one-half at year one, one-fourth at year two, one-fourth at year three) and have a stated exercise price of $1 with an expiration in 2035.
Following these reported transactions and the listed previously outstanding awards and shares, the reporting person’s beneficial ownership is shown as 766,268 shares of common stock (direct).
Positive
- Reported grants are fully disclosed with explicit vesting schedules and exercise price, improving transparency for investors.
- Significant insider stake: Reporting person’s direct beneficial ownership is stated as 766,268 shares, combining vested shares and outstanding awards.
- Change-in-control provisions disclosed: Certain RSUs will settle into common stock upon a defined Change in Control, clarifying treatment of awards in such events.
Negative
- None.
Insights
TL;DR: Officer equity awards increase disclosed insider holdings but represent standard compensation vesting schedules; impact is informational, not a transaction-based purchase signal.
The Form 4 documents grants of 89,100 RSUs and options covering 111,100 shares to Vincent Capponi, with explicit vesting schedules and an exercise price of $1 for the options. The RSUs include tranches that convert on vesting and certain RSUs that accelerate on a defined Change in Control. The disclosures show total direct beneficial ownership of 766,268 shares after accounting for outstanding RSUs and prior holdings. For investors, this is a routine compensation disclosure that clarifies potential future share issuance timing but does not itself provide revenue, earnings, or operational information.
TL;DR: Grants follow multi-year vesting and include change-in-control settlement provisions; governance disclosure is complete and shows ownership concentration.
The filing specifies vesting mechanics: RSUs vest in equal parts at the first and second anniversaries of grant and certain historical RSUs accelerate on a defined Change in Control. Options vest one-half after one year, one-fourth after year two, and one-fourth after year three, with an expiration date in 2035. The Form also itemizes previously granted RSU tranches that may settle upon a Change in Control and discloses 429,668 shares already owned by the reporting person. The filing provides clear, itemized information relevant to compensation oversight and potential future share issuance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 111,100 | $0.00 | -- |
| Grant/Award | Common Stock | 89,100 | $0.00 | -- |
Footnotes (1)
- These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date. Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015; (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and of which 40,500 remain unvested as of the date hereof; and (continued from footnote 3) (iii) 429,668 shares of Common Stock owned by the Reporting Person. These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
